Cardiovascular disease in transgendered people: A review of the literature and discussion of risk

Leighton J Seal1,2,3

Abstract
This review examines the impact of gender affirming hormone therapy used in the transgendered and non-binary populations on cardiovascular outcomes and surrogate markers of cardiovascular health. Current evidence suggests that hormonal therapy for transgendered women decreases or is neutral regarding myocardial infarction risk. There is an increased incidence of venous thromboembolism (VTE), but newer studies suggest that the risk is significantly lower than previously described. For transgendered men, there appears to be an adverse effect on lipid parameters but this does not translate into an increased risk of cardiovascular disease above that of general male population. In all transgendered people, risk factor interventions such as smoking cessation, weight management and treatment of co-morbid conditions are important in optimising cardiovascular health. The effect of gender affirming hormonal therapy in transgendered people is difficult to interpret due to the variety of hormone regimens used, the relative brevity of the periods of observation and the influence of confounding factors such as the historical use of less physiological, oestrogens such as conjugated equine oestrogen and ethinylestradiol which are more pro-thrombotic than the 17β oestradiol that is used in modern practice.

Keywords
Transgender man, transgender woman, cardiovascular risk, hormone replacement therapy

Introduction
Hormone replacement therapy for the majority of transpeople is an important part of their transition process. It is known that sex steroid therapy is associated with cardiovascular risk1–6 but there is poor quality evidence of the extent of this risk in the transgendered population. Cardiovascular risk in this population has been examined by meta-analyses;7–9 however, the literature has been extended with the recent publication of further large studies looking at cardiovascular outcomes in transgendered people, both in the USA10–12 and Europe.13

This review will examine the current evidence on the impact of gender affirming hormonal therapy in the binary transgendered population, on cardiovascular health and surrogate markers of cardiovascular risk such as lipid profile and thrombotic risk. It will also put these findings in the context of the recent studies and also discuss non-hormonal factors that may contribute to adverse cardiovascular outcomes in this population.

Methods
A literature search of the current English language literature was made using the Pub Med database using key words to identify articles relating to cardiovascular health in transgendered people. Key words were transgender, transgendered, transsexual, transman,
transmen, transwoman, transwomen, non-binary, myocardial infarction, MI, thromboembolism, pulmonary embolism, deep venous thrombosis, TE, DVT, PE, stroke, cardiovascular, lipid, metabolic, and meta-analysis.

Where studies were included in a meta-analysis these data were used to give an overview of the effect of gender affirming hormone treatment on an outcome.

Cardiovascular disease and gender

Cardiovascular disease has a major impact on mortality. In the 20th century, it was the major cause of mortality and has only recently been overtaken by malignancy as the leading cause of death in the UK. The risk factors for developing cardiovascular disease have long been divided into modifiable and non-modifiable factors. One of the previously non-modifiable risk factors was gender. There has been and extensive literature on the gender differences in cardiovascular risk, which have usually been attributed to the difference in hormonal milieu between males and females.

Gender terminology and gender dysphoria

People who remain in the gender role they were assigned at birth are termed cisgendered women (a person who was birth assigned female who remains in a female gender role) and cisgendered men (a person who was birth assigned male who remains in a male gender role). An increasing number of people are questioning the gender they were assigned at birth which is termed gender nonconformity. Many of these people decide to change their social gender role to one that is more concordant with their internal sense of gender, the majority of individuals make a binary transition from one gender role to a role that would be viewed as the opposite gender role (from birth assigned male to female; a transgendered woman or from birth assigned female to male; a transgendered man) and a smaller number of people transition to a gender role that is not defined by male or female (non-binary). The majority of people who transition gender role use gender affirming hormone treatment to achieve the secondary sexual characteristics of their desired gender and so their hormone milieu is different to their birth assigned gender.

Gender dysphoria is not a rare condition with an impression of rising incidence. Previous estimates of the incidence ranged between 1:74401 and 1:30,000 for birth assigned males and 1:31,153 to 1:10,000 for birth assigned females. A meta-analysis estimated the prevalence to be 6.8/100,000 for transgendered women and 2.6/100,000 for transgendered men. More up-to-date studies suggest that the incidence is higher, with 0.5–1.3% of birth-assigned males and 0.4–1.2% birth-assigned females identify as a transgendered person. A recent study suggested that approximately 10% of people attending a large single centre gender clinical have a non-binary gender identity. The transgendered population is growing, cardiovascular death has been identified as a significant cause of mortality in this population, and so its management is part of mainstream medicine, and it is not limited to specialist centres.

Cardiovascular risks and endogenous sex steroids

It has been observed across many study populations that males have higher cardiovascular mortality than females certainly until menopause. After menopause, female cardiovascular mortality increases with advancing age and so it is argued that oestrogen is cardio-protective and testosterone is atherogenic. It is known that endogenous ovarian hormone production protects cisgendered women from cardiovascular disease. Women with early menopause before the age of 45, either naturally or surgically induced, are at higher cardiovascular risk compared to women who cease ovarian function later and this is mainly due to coronary heart disease mortality. The role of high androgens levels in the development of cardiovascular disease cisgendered women is less clear. While it is known that high endogenous testosterone is associated with increased cardiovascular risk factors including increased intimal thickness, increased coronary plaques and increased arterial thickness, an association between androgen levels and cardiovascular events could not be established in a 10-year follow-up study. The complicating factor here is that the commonest cause of hyperandrogenism in females is polycystic ovarian syndrome which may be acting as a confounder.

In cisgendered males, it is known that hypogonadism is also associated with increased mortality. Men who have a testosterone level in the lower tertile have been shown to have a mortality nearly twice that of men with testosterone levels in the upper tertile over eight years (hazard ratio (HR) 1.88; 95% CI: 1.34–2.63; p < 0.001). A meta-analysis of hypogonadism in males confirmed that low testosterone and also high oestradiol levels in males are associated with increased cardiovascular disease (HR 0.837(0.823–0.852) for each nmol/L increment of testosterone; p < 0.0001).
Physiologically it appears that abnormally low endogenous production of sex steroids of the birth-assigned gender and the increased levels of sex steroid levels of the opposite gender are associated with higher levels of cardiovascular disease.

**Cardiovascular risks and exogenous sex steroids therapy (HRT)**

**Cisgendered females**

The data on the effects of exogenous oestrogen therapy on cardiovascular events in females comes mainly from trials looking at postmenopausal HRT. The WHI trial in postmenopausal women was constructed on the premise that giving oestrogen to postmenopausal women would restore their cardiovascular protection, however, the trial demonstrated an increase in cardiovascular events which lead to its premature termination. For all cardiovascular events, hazard ratios were increased at 1.13 (95% CI: 1.02–1.25) for the conjugated equine oestrogen (CEE) + medroxyprogesterone acetate (MPA) arm of the trial. After adjusting for multiple analyses the hazard ratios for stroke, total myocardial infarction (MI), coronary artery intervention and cardiovascular deaths were not increased; however, there was increased risk of thromboembolic events that remained at 2.11 (95% CI: 1.26–3.55).

A subsequent trial looking at the effect of CEE alone in hysterectomised females found the hazard ratio for all cardiovascular events was still increased to 1.11 (95% CI: 1.01–1.22) but this was shown to be age dependent; the hazard ratios for MI increased by decade of age (0.55 for 50–59 years, 0.95 for 60–69 years and 1.24 for 70–79 years). These data suggest that the use of oestrogen without progestin given to females at an earlier age within 10 years of menopause results in the least impact on cardiovascular events.

Further meta-analysis of 23 randomised control trials of women receiving HRT again demonstrated a 32% reduction in cardiovascular events; these data suggest that, providing there is not a significant time without sex steroid exposure, oestrogen HRT can maintain cardiovascular health. Even though high endogenous production of testosterone is associated with increase in markers of cardiovascular risk, the use of therapeutic testosterone replacement in women has not demonstrated any adverse impact on cardiovascular health, suggesting it is safe when doses are given to achieve testosterone values in the female range.

**Cisgendered males**

The treatment of hypogonadism in males with testosterone therapy is associated with varying results with regards to cardiovascular safety. Some have advocated transdermal replacement as a more physiological route. There have been several meta-analyses and reviews on this topic; six out of seven of these did not demonstrate any increase in cardiovascular events. These data have been reviewed in the Lancet with summary estimates demonstrating no significant association between exogenous testosterone and cardiovascular events ranging from [RR 1.07–1.82].

There has, however, been controversy about the use of testosterone in elderly men with three trials suggesting there is an increase in cardiovascular risk. In the first trial of 209 elderly men, the trial was stopped prematurely as there was a 5.8 fold (95% CI: 2.0–16.8) increased adjusted odds ratio of cardiovascular-related events. This trial, however, was criticised as the dose of testosterone used (100 mg topical gel) was extremely high, and it is double a standard hormone replacement dose. In an elderly group of men, it is perhaps not surprising that adverse events occurred. Indeed there was a 3% increase in haematocrit which may have increased plasma viscosity and contributed to this increase in cardiovascular events.

The second study reported that testosterone replacement therapy resulted in an increased risk of MI within 90 days of receiving a testosterone prescription in men ≥65 years old [odds ratio 2.2] and those <65 years with pre-existing heart disease, [odds ratios 2.9].

In the third study, men with hypogonadism who underwent coronary angiography and were replaced with testosterone had an increase in adverse outcomes when using a composite endpoint of myocardial infarction, stroke and death. (HR 1.299 95% CI: 1.04–1.58).

This study was, however, criticised as the biological effects of testosterone therapy were not reported and only 1/5 of the testosterone prescriptions were ever filled suggesting the hypogonadism was not corrected.

Other studied contradict these data. Testosterone replacement to physiological levels in hypogonadal men resulted in an improvement in endothelial function and arterial stiffness. An extensive meta-analysis of testosterone therapy for hypogonadism in men did not demonstrate any effect of testosterone therapy on all-cause mortality (OR 1.12 95% CI: 0.7–1.81), risk for MI (OR 1.09 95% CI (0.29–2.82)), or need for coronary artery vein grafting (OR 1.35 95% CI (0.26–6.98)), suggesting that on balance testosterone therapy with the aim of replacement to the normal male range is safe.
**Transgendered women**

Oestrogen therapy and androgen suppression in transgendered females simultaneously has a positive and negative effect on cardiovascular risk factors. The metabolic effects of oestrogen therapy are centred around alteration in liver function and the effects of oestrogen on lipid parameters. There appears to be a decrease in hepatic lipase activity by 64% and of lipoprotein lipase by 23%. Hepatic lipase decreases HDL-cholesterol levels, by catalysing the hydrolysis of triacylglyceride which results in the conversion of lipid-enriched HDL 2 particles to lipid-poor HDL 3 particles; it also increases the formation of small, dense LDL particles both of which are highly atherogenic. Reducing levels of hepatic lipase may reduce the formation of these atherogenic lipid particles.

Cross-sectional studies, however, suggest that oestrogen has a positive effect on plasma lipids with higher HDL +0.2 mmol/L (6 mg/dl) and 0.16 mmol/L (6 mg/dl)12 and lower LDL as the LDL-C level was statistically significantly lower in oestrogen treated transgendered female group (5.71 mmol/L; 95% CI: 5.96–5.44 mmol/L; I2 = 0%) (220.3 mg/dL; 95% CI: 230.7–210.0 mg/dL; I2 = 0%). There was no change in other lipid parameters. These studies have small participant numbers making the reliability of the findings uncertain.

The effect of oestrogen treatment in transgendered women has been described in 3 meta-analyses. The use of oestrogen therapy in transgendered females showed no statistically significant difference in serum LDL-C, HDL-C, and total cholesterol levels but there was an increase in plasma triglyceride levels after 24 months 0.35 mmol/L (95% CI: 0.09–0.62 mmol/L) and a decrease in plasma HDL levels (0.73 mmol/L) (95% CI: 0.3 to 0.02 mmol/L), both of which are pro-atherogenic.

Body composition also changes. There is a significant increase in body weight (+3%; 95% CI: +2% to +5%; p < 0.001) and total body fat (+28%; 95% CI: +24% to +32%, p < 0.001). At the same time there is a reduction in lean body mass –3% (95% CI: −4% to −2%, p < 0.001). Gender affirming hormone therapy has also been shown to increase visceral fat. These changes in body composition would be expected to have a negative impact on cardiovascular risk.

In a study by Elbers et al, employing euglycaemic clamping, insulin sensitivity appeared to be reduced (by 33%) with a commitment increase in insulin levels (by 50%). Fasting glucose however appeared not to be affected. Other studies have demonstrated no change in either fasting insulin levels, HOMA-IR or fasting glucose levels.

There are differing reports on the effect of gender affirming hormonal therapy in blood pressure in transgendered females. In one large cohort study of 247 individuals oestrogen had no effect on blood pressure but in another there was a significant increase of systolic blood pressure by 7.2 mmHg and diastolic blood pressure of 5.7 mmHg.

Elevated plasma level of total homocysteine had been shown to be an independent risk factor independent for CVD. Total homocysteine levels vary between the sexes; the levels are approximately 10–15% lower in women. Oestrogen therapy in transgendered females reduced plasma homocysteine levels 8.2 mmol/L to 5.7 mmol/L (p = 0.001), this effect is independent of the route of administration of oestrogen. This may have a beneficial effect on cardiovascular risks.

Oestrogens alter prothrombotic and inflammatory markers in transgendered women that may have a role in cardiovascular disease. It has been demonstrated that oral ethinylestradiol in combination with cyproterone acetate but not transdermal 17Beta oestradiol increases CRP and decreases tissue plasminogen activator. Other studies have however shown no effect on CRP and so the impact of oestrogen therapy on prothrombotic changes is unclear. It is of note however that one of the long term outcome studies suggest that the increase in cardiovascular risk was limited to current users of ethinylestradiol and the finding that ethinylestradiol promotes a more prothrombotic milieu would provide a possible explanation for this result.

The current literature demonstrates that oestrogen therapy in transgendered females can result in a mix of changes to physiological parameters. Some increase cardiovascular risk; increased body fat, increased weight, increased visceral fat, reduced lean mass, prothrombotic blood changes, and higher triglyceride. Others decrease cardiovascular risk such as reduced LDL cholesterol and increases plasma homocysteine levels. With studies showing an increased rate of stroke and thromboembolism it is likely that the pro-atherogenic changes predominate.

**Transgendered men**

There are significant gender differences in lipid parameters, with males having higher total cholesterol, LDL cholesterol and triglyceride, with lower plasma HDL cholesterol. As expected, testosterone therapy in transmen adversely alters their lipid parameters. A recent meta-analysis of the available data demonstrated there was no change in total cholesterol or LDL cholesterol but there was a minor increase in triglyceride (0.35 [CI 0.09–0.62] mmol/L) and a decrease in plasma HDL levels (−0.73 [CI −0.3 to 0.02] mmol/L), both of which are pro-atherogenic. A more recent meta-analysis showed that the changes in lipid parameters
were progressive with time over 24 months so that by 24 months of testosterone therapy TG levels were higher (+0.24 mmol/L; 95% CI: 0.15–0.32 mmol/L) compared with baseline; the serum LDL-C level showed a statistically significant increase (+0.46 mg/dL; 95% CI: 0.29–0.63 mg/dL) and a decrease in HDL-C level (-0.02 mg/dL; 95% CI: -0.03–0.01 mg/dL; -0.21 mg/dL; 95% CI: -0.34 to -0.1 mg/dL) (-8.5 mg/dL; 95% CI: -13.0 to -3.9 mg/dL). Total serum cholesterol level did not show a statistically significant change.

With regards to body composition, there is an increase in weight in transgendered men treated with testosterone of +3% (95% CI: 2%; 4%, p < 0.001) but this is accompanied by a decrease in total body fat of -9% (95% CI: -12%; -7%, p < 0.001) and an increase in total lean body mass of +10% (95% CI: 9%; 11%, p < 0.001). On balance, this would be a positive change for metabolic risk.

In transgendered men, testosterone therapy has no effect on fasting glucose, fasting insulin or glucose utilisation. Studies are contradictory with regards to testosterone’s effect on blood pressure in transgendered males. Six studies assessed effects testosterone therapy on blood pressure levels in transgendered men. In one study, there was an increase in both systolic and diastolic blood pressure, in two studies there was an increase only in systolic blood pressure and in two others no significant changes were found. In another study, there was a decrease in systolic and diastolic blood pressure levels.

Testosterone therapy increases plasma homocysteine levels in transgendered men to 7.7 mmol/L to 9.0 mmol/L (p < 0.005) which could have a negative impact on cardiovascular risk.

It is interesting that these changes in lipid profile do not appear to translate into an alteration in cardiovascular risk, as there is no increase in cardiovascular mortality in treated transmen; indeed one study suggested the MI rate is approximately one-third of that expected in the general male population. These findings have been confirmed in long-term follow-up studies where the standard mortality ratio for transmen is not different from the general population.

Other risk factors
The metabolic factors for cardiovascular disease other risk factors can have a significant effect in the transgendered population.

Smoking
Smoking is an important risk factor for cardiovascular events and tobacco use has been demonstrated to be high in the transgendered population. The incidence of smoking in the reports series varies from 15% to 63.5% in transgendered women and 18% to 74.4% in transgendered men. Smoking is such a powerful co-factor in cardiovascular disease that it may represent a considerable confounder when looking at the cardiovascular risk in transgendered people.

It is interesting that the rate of smoking in transgendered men is higher than that of transgendered women and yet cardiovascular mortality does not seem to be impacted. In two large series, the rates of MI and stroke in transgendered men are not higher than either birth-assigned females or birth-assigned males. In another series of 816 transgendered people, the MI rate for transgendered men was one-third that of the general population (SIR 0.05 [0.24–0.91]), despite a high rate of tobacco use at 43–46%. More recently, however, a large community-based study of 1.4 million people suggests that smoking rates in transgendered men and women were higher than the cisgendered population (smoking rate transgendered men 19.3%, transgendered women 20.3%, cisgendered men 18.6%, cisgendered women 14.4%) and here MI rates were higher in transgendered men compared to cisgendered men (OR 2.53 95% CI: 1.14–5.63) and cisgendered women (OR 4.90 95% CI: 2.21–10.90).

HIV infection
The incidence of HIV infection in the transgendered female population appears to be increased compared to the general population. It is has been estimated that just under a third of transgendered women in the USA may be seropositive. A systematic review which looked at 39 studies suggested a global HIV prevalence rate of 19.1% in transgendered women. Interestingly, in this review a much higher HIV burden was found in transgendered women of colour, Hispanic 49.6% and African American transgendered women 48.1% compared to Caucasian transgendered women at 3.5%.

As ethnic origin is a cardiovascular risk factor per se, this could mean transgendered women living with HIV have a very high cardiovascular risk.

The association between HIV infection and cardiovascular disease is caused by a combination of traditional risk (e.g. smoking, diabetes, lipid abnormalities), disease-specific risk factors (e.g. chronic inflammatory response and lipoprotein-α levels), the effect of antiretroviral agents, the virus itself and consequences of the immune response. Coronary artery disease is one of the leading causes of death in HIV-infected patients.

One study examined the incidence of coronary risk factors in transgendered females compared to a cisgendered male control group and found that there were no
difference in the incidence of cardiovascular risk factors between the groups.68 They did, however, note that the transgendered female group did have suboptimal HIV control. This heightened immune activation may be a mechanism by which accelerated cardiovascular disease can occur.

None of the outcome studies in transgendered people so far have commented on the incidence of HIV seropositivity in the reported populations and so cannot be excluded as a cofactor increasing cardiovascular disease incidence.

**Stress**

Psychological distress is a well-established CVD risk factor, as it is believed to result in atherosclerosis by immune dysfunction and maladaptive metabolic responses.69 Transgendered people are known to suffer from minority stress.70 Stigmatisation which is experienced by people in this community enhances distress via unhealthy coping mechanisms such as concealment.70

In the US transgender survey, 39% of respondents reported severe psychological distress. This figure is eight times higher than the general population.70 It known that stressful events, chronic stress or repeated acute stress places people at a higher cardiovascular risk.69 Undertaking treatment for gender dysphoria has been shown to successfully reduce stress, improve quality of life and also to reduce tobacco use.71,72 These measures may obviate some of the cardiovascular risk associated with gender affirming hormonal therapy in the transgendered population.

**Cardiovascular outcomes in transgendered people**

**Cardiovascular mortality**

Long-term outcome studies have demonstrated that mortality is increased in the transgendered population.21,22 Although the major causes of death in these studies appeared to be from suicide, complications related to HIV and malignancies cardiovascular risk was also raised in both these studies.21,22 The first study was a population-based matched cohort study in Sweden including 324 participants with an average follow-up of 11.4 years and it demonstrates a HR of 2.5 (1.2–5.3) for death by cardiovascular disease. This study is of limited use in dissecting the cause of this mortality, as it was not stratified for gender, hormone type used or smoking status. A single-centre cohort observational study of 996 participants with an average follow-up of 18.5 years, reported that the standard mortality ratio was only raised in the transgendered female population (SMR 1.51(95% CI: 1.47–1.55) and not the transgendered male population (SMR 1.12 (95% CI: 0.87–1.42). These data suggest that increased cardiovascular mortality exist in the transgendered population. However, this increase in cardiovascular morbidity is limited to the transgendered female population.

**Myocardial infarction (MI)**

In the Asscheman cohort study, ischemic heart disease was the cause of death in 18 subjects (SMR 1.64; 95% CI: 1.43–1.87).22 These findings have been repeated in the USA with data from the Behavioural Risk Factor Surveillance System, with a population of 691 transgendered people. The adjusted odds ratio for MI was increased to 1.82 (95% CI: 1.22–2.72) but the study did not stratify the data by birth assigned gender.11

In contrast, other studies have not shown an increase in myocardial infarction; in a population of 352 transgendered people with 7.4 years of follow-up, again there was no significant increase in the incidence of MI compared to control men, although the rate was increased compared to control women (18.7/1000 (compared to 12.5/1000 men p NS and 0/1000 women p = 0.001). In another shorter study, the rate of MI was half that expected compared to birth assigned males (SIR 0.5 (95% CI: 0.24–0.91)).

A large electronic record cohort study of 4960 transgendered people with four years of follow-up demonstrated no increase in MI compared to reference males or females (HR 1.0 (95% CI: 0.3–3.2 compared to males; HR 2.4 95% CI: 0.6–9.4)).

Similar findings occurred in a large cohort study in Holland of 6793 participants with mean follow-up of 9.07 years. This study reported SIR for MI of 0.79 (95% CI: 0.57–1.11 compared to cisgendered males) and 2.64 (95% CI: 1.81–3.72 compared to cisgendered females p < 0.01).13

A very recent study from the USA looked at a very large population sample of 1,842,439 which included 340,365 transgendered women. This study demonstrated that there was a significantly increased rate of MI in transgendered women compared to cisgendered women (7.8% vs. 3.1%; p < 0.01) and cisgendered men (7.8% vs. 5.6%; p < 0.01). However, after adjusting for age, diabetes mellitus, chronic kidney disease, smoking, hypertension, hypercholesterolemia, and exercise, transgendered women only had a significantly increased risk of MI compared to cisgendered females (odds ratio [OR], 2.56; 95% CI: 1.78–3.68; p < 0.01) but not cisgendered men.12

For transgendered men, MI rates were higher when compared to cisgendered women (7.2% compared to 3.1%; p < 0.010), but there was no difference when
compared to cisgendered men (7.2% compared to 5.6%; \( p = 0.30 \)). After adjustment for cardiovascular risk factors, however, the study demonstrated that transgendered men had an increased risk for MI compared to both cisgendered populations (OR 2.53 95% CI: 1.14–5.63 compared to cisgendered men; OR 4.90 95% CI: 2.21–10.90 compared to cisgendered women).\(^{12}\)

This finding is in contrast with the findings of the other studies looking at MI in transgendered females where the MI rate is lower than the cisgendered male\(^{63}\) population and also for transgendered men where studies have shown the MI rate is either lower or similar to the cisgendered male population.\(^{10,23,63}\) Although there was a large study population, the investigators used self-reporting of trans status to identify the transgendered population in the study rather than a diagnostic assessment as part of a gender dysphoria assessment and treatment programme which has been used in the other reported series. This may mean that the two populations differ significantly with regards to access to gender affirming hormone therapy. Indeed this study could not comment on whether the individuals were taking gender affirming hormonal therapy to treat their gender dysphoria. It may therefore be that case that taking gender affirming hormonal therapy to treat gender dysphoria has a positive effect on cardiovascular outcomes in transgendered people as MI rates are higher in a self-reported transgendered population compared to those in a treatment and assessment programme.

This study emphasises the importance of cardiovascular co-morbidities such as smoking, reduced exercise, diabetes and non-Caucasian ethnic origin, all of which were seen in higher numbers in the transgendered population.

The balance of evidence appears to support the finding that gender affirming hormonal therapy in transgendered females may reduce MI rate but not to the level of cisgendered women. In transgendered men, the risk of MI is higher than the cisgendered female population but probably no higher than the cisgendered male population.

**Stroke**

Five studies have reported on the incidence of stroke in the transgendered population. In the Asscheman study, five people died of stroke and they reported a non-significant SMR of 1.26 (95% CI: 0.93–1.64).\(^{73}\) Similarly, Wierckx reported an incidence of stroke of 23.4/1000 which was significantly higher than control men (9.4/1000; \( p = 0.03 \)) but not significantly different when compared to control females (14.9/1000).\(^{44}\) In the USA, Meyer reported a reduced stroke incidence in the transgendered population OR 0.65 (95% CI: 0.43–0.99).\(^{11}\)

Two larger studies, however, suggest that the incidence of stroke was increased.Nota et al. reported a significantly increased rate of stroke in transgendered females with a SIR 1.8 (95% CI: 1.23–2.56 compared to cisgendered males) and 2.42 (95% CI: 1.65–3.42 compared to cisgendered females).\(^{74}\) In the Gatahun paper, however, overall stroke risk was not increased compared with reference males (HR 1.2 995% CI: 0.9–1.7) but increased compared with reference females (HR 1.9 (95% CI: 1.3–2.6)).\(^{10}\) In a subgroup analysis looking at those that commenced oestrogen therapy during follow-up, the incidence of stroke appeared to increase after six years of treatment compared to both reference males and reference females.\(^{10}\)

These data give conflicting results with regards to stroke rates in the transgendered female population. Most of the studies suggest that stroke rates are between that seen in cisgendered males and cisgendered females. In contrast, one large cohort study suggests that increased stroke incidence does not become apparent until six years of exposure.\(^{10}\) However, a moderately sized study a with follow-up duration of three times this duration, refuted this finding.\(^{22}\)

**Thromboembolism**

There is strong evidence that oestrogen increases thromboembolic events in cisgendered women. The WHI study confirmed that DVT incidence was increased (HR 1.87 (95% CI: 1.37–2.54) for the CEE + MPA trial and 1.48 (95% CI: 1.06–2.07) and pulmonary embolus (HR 1.98 (95% CI: 1.36–2.87)).\(^{75}\) In the oestrogen only arm of the trial, this translated to an extra 7–12 deep vein thromboses/10,000 person-years.\(^{76}\) A Cochrane review found that hormone replacement therapy was associated with an increased risk of venous thromboembolism in all populations of post-menopausal women: whether HRT started <10 years post menopause [RR 1.74 (95% CI: 1.11–2.73)], >10 years post menopause [RR 1.96 (95% CI: 1.37–2.80)] or those with pre-existing cardiovascular disease [RR 2.02 (95% CI: 1.13–3.62)].\(^{77}\) The increased risk represents 5–12 additional cases of venous thromboembolism (VTE) per 1000 people.\(^{77}\) The increased risk was largely driven by women on combination hormone therapy.

The route of oestrogen delivery, and type of progestin used in HRT also have an influence on thromboembolic risk. In a case-control study of post-menopausal women, the rate of VTE was raised in current oral oestradiol hormone therapy users,\(^{78}\) (adjusted OR 4.2 (95% CI: 1.5–11.6) but this was not seen in transdermal oestrogen (OR 0.9 (95% CI: 0.4–2.1).
Non-pregnane progestins (nomegestrol acetate and promegestone) were associated with increased VTE of OR 3.9 (95% CI: 1.5–10.0) whereas no differences were noted with micronised progesterone or pregnane derivatives (medroxyprogesterone acetate, dydrogesterone, medrogestone, chlormadinone acetate and cyproterone acetate).

In younger women, although stroke and MI risk is low, that risk is increased by the use of the synthetic oestrogen ethinylestradiol. The absolute risk is dose dependant, with oral contraceptives that contained ethinylestradiol at a dose of 20 mg/day increasing the absolute risk by 0.9–1.7 fold and with those containing ethinylestradiol at a dose of 30–40 mg/day by a factor of 1.3–2.3. As transgendered women usually take doses 2–5 times higher than this, and safer alternatives are now available, the use of ethinylestradiol is best avoided.

Another important cofactor is smoking. Smoking by women taking the oral contraceptive pill increases the risk of stroke and DVT. The thromboembolic risk is modulated by several factors such as the oestrogen type, the route of delivery and the co-administered androgen-lowering medications. Ethinylestradiol alters the plasma concentrations of protein S, C and prothrombin, which results in a procoagulant haemostatic profile in transgendered women. Oral ethinylestradiol 100 mcg daily in combination with cyproterone acetate 100 mg/day caused a significant increase in activated protein C (APC) resistance (nAPCsr 1.2–4.1 U); however, transdermal oestradiol 100 mcg twice per week and cyproterone acetate 100 mg or cyproterone acetate monotherapy had a minor effect (1.3 U ± 0.6 to 2.0 U ± 2.0 and 1.4 ± 0.6 to 1.8 ± 0.9, respectively). Ethinylestradiol and cyproterone acetate also decreased the coagulation inhibitor Protein S. These changes were not observed when either transdermal oestradiol or oral oestrogen valerate was used.

There have been reports of a possible link between testosterone replacement therapy use and increased VTE risk in men; however, these studies were criticised for including data on events such as avascular necrosis of the femoral head which are not classically viewed as VTE events. Larger epidemiological studies have demonstrated that there is no link between testosterone therapy and thrombembolism risk, and these data were summarised in a recent meta-analysis (OR 1.41 (95% CI: 0.96–2.27)).

In transgendered women, initial studies suggested that gender affirming hormone therapy use was associated with a 45-fold increase risk of VTE when ethinylestradiol and cyproterone acetate was used. This appeared to be age related as women over 40 years old had a deep venous thrombosis rate of 12% and those under 40 only 2.1%. By changing to transdermal oestrogen after the age of 45 years in transgendered women, this group reduced the rate of DVT from 12% to 2.6% in their clinic population. The majority of these incidents occur during the first two years of treatment. There is, however, an on-going risk of 0.4% per year.

A recent meta-analysis of 1767 individuals on oestrogen therapy found VTE rates of 0–5% in 10 studies with variable durations of follow-up. The rate of VTE was not increased in transgendered men.

Since that meta-analysis, two new large trials have reported VTE rates. Nota et al. have reported significantly increased rate of VTE in transgendered women with a SIR of 4.55 (95% CI: 3.59–5.69 compared to cisgendered males) and 5.52 (95% CI: 4.36–6.9 compared to cisgendered females). There was no increase in VTE in transgendered men a SIR 0.36 (95% CI: 0.06–1.19 compared to cisgendered males) and 0.41 (95% CI: 0.07–1.37 compared to cisgendered females). In the large electronic data base cohort study reported by Getahun et al., the risk for VTE was increased in the transgendered female population – HR 1.9 (95% CI: 1.4–2.7) compared to reference males and 2.0 (95% CI: 1.4–2.8) compared to reference females. This study, in contrast to all the previously reported studies, report suggested that VTE risk increases after two years of oestrogen therapy. In the earlier literature, the majority of VTE events occurred in the first two years of treatment, and further studies are needed to examine the temporal relationship between thromboembolic events and gender affirming hormone therapy in transgendered women. In the Getahun et al. study, again there was no increase in VTE risk in transgendered males. These new studies suggest a much lower risk of VTE which is approximately 2-fold higher than the control populations compared to the previously reported 20-fold increased risk.
important. A study demonstrated that the incidence of VTE in a population of 330 transwomen was 0.6% for those treated with oral oestriadiol in doses of up to 10 mg daily but the incidence of VTE was eight-fold higher in those treated with CEE. These data would support the hypothesis that oestrogen type not route of administration has more impact on DVT rate in transwomen.\textsuperscript{89} This has also been recognised in contraceptive practice where the prothrombotic effect of ethinylenesradiol has been ascribed to its molecular structure rather than to the first-pass liver metabolism creating thrombogenic oestrogen breakdown products.\textsuperscript{87}

**Hormonal factors in cardiovascular disease in transgendersed people**

We know from long-term outcome studies that the use of ethinylestradiol in transwomen is associated with increased cardiovascular risk (adjusted OR 3.64 (95% CI: 1052–8.73) and this risk is not seen in past users of ethinylestradiol, 17β-oestradiol preparations or conjugated equine oestrogen (CEE)).\textsuperscript{22} The problem with the meta-analyses so far is that few of the transgendered women were treated with 17β-oestradiol, the majority were treated with either ethinylestradiol or CEE, and only 7% were on 17β-oestradiol and GnRH analogues. This is an area where further research is needed to characterise the effects of 17β-oestradiol preparations rather than ethinylestradiol or CEE on lipid parameters.\textsuperscript{7}

In modern practice, the majority of clinics internationally have moved to using 17β-oestradiol rather than other oestrogen preparations when providing gender affirming hormonal therapy for transgendered women and this may have contributed to the reduced VTE risk observed in the newer larger studies. This change in clinical practice, however, acts as a confounding factor because the long-term follow-up studies include individuals treated with both types of oestrogen regimens\textsuperscript{13,21,22} making the interpretation of long-term data difficult in this population.

Smoking is also a significant confounder in these studies. We know from the combined contraceptive pill studies that the incidence of VTE is increased in smokers by approximately two-fold, and smoking in combination with obesity increases this risk to nine-fold.\textsuperscript{88} An important feature of the protocol used in the largest UK clinics is that the client must stop smoking in order to receive high-dose oestrogen,\textsuperscript{89} which is an attempt to reduce the VTE risk of this patient population. The incidence of smoking in the recent Dutch long-term study is estimated at 43–46%\textsuperscript{13} whereas the incidence of smoking at the time of a cardiovascular event in the Getahun et al. report was 20%.\textsuperscript{10}

As smoking is a strong cofactor in both VTE and cardiovascular events in transgendersed people,\textsuperscript{23} these different levels of tobacco use across cohorts may have a significant impact on the rates of cardiovascular events making the interpretation of results difficult. In UK practice, individuals strongly are encouraged to cease smoking before hormone therapy is initiated.\textsuperscript{89}

Finally, the method used for testosterone suppression may have an influence on the rate of cardiovascular disease. In Europe, cyproterone acetate is the mainstay of androgen suppression. This antiandrogenic progestin may increase the risk of thrombembolism when given in combination with oestrogen. We know from the cisgendered female population that oestrogen progestin HRT is more thrombogenic than oestrogen alone HRT.\textsuperscript{75}

In the UK, GnRH analogues form the mainstay of androgen suppression.\textsuperscript{90} In Europe because of the expense of these medications, it is more usual to use cyproterone acetate for androgen suppression. One study has made a direct comparison between cyproterone acetate and leuprolide for androgen suppression in combination with transdermal 17β-oestradiol. Leuprolide was equally effective at inducing androgen suppression but it was less likely to induce hyperprolactinaemia. More interestingly 17β-oestradiol and leuprolide therapy increased HDL cholesterol (+0.2 ± 0.5 mmol/L) whereas cyproterone acetate and 17β-oestradiol therapy decreased HDL-cholesterol (−0.2 ± 0.3 mmol/L).\textsuperscript{91} This may be important in the development of cardiovascular disease which may alter the rates.

In transgendered men, it is interesting that adverse effects of androgens on lipid profile do not appear to translate into an alteration in cardiovascular risk. There is no increase in cardiovascular mortality in testosterone-treated transgendered men; indeed the MI rate is between one-third expected in the cisgendered male population\textsuperscript{63} and expected male gender population norms.\textsuperscript{13} These findings have been confirmed in long-term follow-up studies where the standard mortality ratio for transmen is not different from the general population.\textsuperscript{22} These data suggest that cardiovascular risk factors have less of an impact on cardiovascular disease in transgendered men compared to cisgendered men. The mechanism for this would be interesting to explore in future studies looking at the impact of the protective oestrogenic environment in early life on future cardiovascular risk.

**Conclusion**

Current evidence suggests that hormonal therapy for transgendered women decreases or is neutral regarding MI. There is an increased incidence of VTE, but newer
studies suggest that the risk is significantly lower than previously described. The studies available looking at more modern regimens are, however, scarce and currently have short-term follow-up duration. Therefore, we do not yet know whether these treatment regimens will improve cardiovascular risk. Stroke risk may be increased and further studies are required to clarify the long-term cardiovascular risks of gender affirming hormonal therapy in transgendered women.

For transgendered men, there appears to be an adverse effect on lipid parameters, but this does not translate into an increased risk of cardiovascular disease. The younger age of transgendered men in the studies so far may mean that a longer follow-up is needed to assess whether there is truly an increased cardiovascular risk.

In all transgendered people, cardiovascular risk factor interventions such as smoking cessation, weight management and treatment of co-morbid conditions are important in optimising cardiovascular health.

The effects of gender affirming hormonal therapy on transgendered people’s cardiovascular health are difficult to interpret due to the variety of hormone regimens used, the relative brevity of the periods of observation and the influence of confounding factors. There is still need for further research in this area.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethical approval

Not Required

Guarantor

LJS

Contributorship

The author confirms he has contributed to the intellectual content of this paper and has met the following four requirements: (a) significant contribution to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; (c) final approval of the published article; and (d) agreement to be accountable for all aspects of the article that’s ensuring that questions related to the accuracy or integrity or any part of the article are a property investigated and resolved.

ORCID iD

Leighton J Seal  https://orcid.org/0000-0001-8151-8634

References

1. Howard BV and Rossouw JE. Estrogens and cardiovascular disease risk revisited: the Women’s Health Initiative. Circ Opin Lipidol 2013; 24: 493–499.
2. El Khoudary SR. Gaps, limitations and new insights on endogenous estrogen and follicle stimulating hormone as related to risk of cardiovascular disease in women traversing the menopause: a narrative review. Maturitas 2017; 104: 44–53.
3. Harvey RE, Coffman KE and Miller VM. Women-specific factors to consider in risk, diagnosis and treatment of cardiovascular disease. Womens Health (Lond Engl) 2015; 11: 239–257.
4. Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One 2014; 9: e85805.
5. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med 2010; 363: 109–122.
6. Vigen R, O’Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013; 310: 1829–1836.
7. Elam MB, Garcia MZ, Murad MH, et al. Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses. Clin Endocrinol (Oxf) 2010; 72: 1–10.
8. Elbers JM, Giltay EJ, Teerlink T, et al. Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clin Endocrinol (Endocrinol) 2003; 58: 562–571.
9. Maraka S, Singh Ospina N, Rodriguez-Gutierrez R, et al. Sex steroids and cardiovascular outcomes in transgender individuals: a systematic review and meta-analysis. J Clin Endocrinol Metab 2017; 102: 3914–3923.
10. Getahun D, Nash R, Flanders WD, et al. Cross-sex hormones and acute cardiovascular events in transgender persons: a cohort study. Ann Intern Med 2018; 169: 205–213.
11. Meyer IH, Brown TN, Herman JL, et al. Demographic characteristics and health status of transgender adults in select US regions; behavioral risk factor surveillance system, 2014. Am J Public Health 2017; 107: 582–589.
12. Alzahrani T, Nguyen T, Ryan A, et al. Cardiovascular disease risk factors and myocardial infarction in the transgender population. Circ Cardiovasc Qual Outcomes 2019; 12: e005597.
13. Nota NM, Wiepjes CM, de Blok CJM, et al. Occurrence of acute cardiovascular events in transgender individuals receiving hormone therapy. Circulation 2019; 139: 1461–1462.
14. Wilson L, Bhatnagar P and Townsend N. Comparing trends in mortality from cardiovascular disease and cancer in the United Kingdom, 1983-2013: joinpoint regression analysis. Popul Health Metr 2017; 15: 23.
Committee on Understanding the Biology of Sex and Gender Differences, Wizemann TM and Pardue ML, et al. *Exploring the biological contributions to human health: does sex matter?* Washington, D.C.: National Academy Press, 2001.

Weden MM and Brown RA. Historical and life course timing of the male mortality disadvantage in Europe: epidemiologic transitions, evolution, and behavior. *Soc Biol* 2006; 53: 61–80.

Wilson P, Sharp C and Carr S. The prevalence of gender dysphoria in Scotland: a primary care study. *Br J Gen Pract* 1999; 49: 991–992.

Arcelus J, Bouman WP, Van Den Noortgate W, et al. *Winter S, Diamond M, Green J, et al. Transgender people: health at the margins of society. Lancet* 2016; 388: 390–400.

Lucy E, Laura SB, Craig R, et al. A comparison of the presenting issues and desired outcomes of people with a non-binary gender identity, between those assigned male at birth and those assigned female at birth at the UK charing cross NHS gender identity clinic. Rome: EPATH, 2019.

Dhejne C, Lichtenstein P, Boman M, et al. Long-term follow-up of transsexual persons undergoing sex reassignment surgery: cohort study in Sweden. *PLoS One* 2011; 6: e16885.

Asscheman H, Giltay EJ, Megens JA, et al. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. *Eur J Endocrinol* 2011; 164: 635–642.

Wierckx K, Elaut E, Declercq E, et al. Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study. *Eur J Endocrinol* 2013; 169: 471–478.

Irwig MS. Cardiovascular health in transgender people. *Rev Endocr Metab Disord* 2018; 19: 243–251.

Waldron I. What do we know about causes of sex differences in mortality? A review of the literature. *Popul Bull UN* 1985; 18: 59–76.

Trovato F and Lalu NM. Contribution of cause-specific mortality to changing sex differences in life expectancy: seven nations case study. *Soc Biol* 1998; 45: 1–20.

Atsma F, Bartelink ML, Grobbee DE, et al. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. *Menopause* 2006; 13: 265–279.

Muka T, Oliver-Williams C, Kunutsor S, et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. *JAMA Cardiol* 2016; 1: 767–776.

Armeni E and Lambrioudaki I. Androgens and cardiovascular disease in women and men. *Maturitas* 2017; 104: 54–72.

Schaffrath G, Kische H, Gross S, et al. Association of sex hormones with incident 10-year cardiovascular disease and mortality in women. *Maturitas* 2015; 82: 424–430.

Ullah MI, Washington T, Kazi M, et al. Testosterone deficiency as a risk factor for cardiovascular disease. *Horm Metab Res* 2011; 43: 153–164.

Shores MM, Matsumoto AM, Sloan KL, et al. Low serum testosterone and mortality in male veterans. *Arch Intern Med* 2006; 166: 1660–1665.

Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *JAMA* 2002; 288: 321–333.

Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. *JAMA* 2007; 297: 1465–1477.

Salpeter SR, Walsh JM, Greyber E, et al. Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. *J Intern Med* 2006; 21: 363–366.

van Staa TP and Snaefel JM. Study of adverse outcomes in women using testosterone therapy. *Maturitas* 2009; 62: 76–80.

Simes SM and Snubes MC. Reaction to the recent publication by rosemary basson entitled 'testosterone therapy for reduced libido in women'. *Ther Adv Endocrinol Metab* 2011; 2: 95–96.

Ullah MI, Riche DM and Koch CA. Transdermal testosterone replacement therapy in men. *Int J Androl* 2014; 8: 101–112.

Onasanya O, Iyer G, Lucas E, et al. Association between exogenous testosterone and cardiovascular events: an overview of systematic reviews. *Lancet Diabetes Endocrinol* 2016; 4: 943–956.

Riche DM, Baker WL and Koch CA. Deaths and cardiovascular events in men receiving testosterone. *JAMA* 2014; 311: 963–964.

Deutsch MB, Bhakri V and Kubicek K. Effects of cross-sex hormone therapy on transgender women and men. *Obstet Gynecol* 2015; 126: 605–610.

Fernandez JD and Tannock LR. Metabolic effects of hormone therapy in transgender patients. *Endocr Pract* 2016; 22: 383–388.

Defreyne J, Van de Bruaene LDL, Rietzschel E, et al. Effects of gender-affirming hormones on lipid, metabolic, and cardiac surrogate blood markers in transgender persons. *Clin Chem* 2019; 65: 119–134.

Gooren LJ, Wierckx K and Giltay EJ. Cardiovascular disease in transsexual persons treated with cross-sex hormones: reversal of the traditional sex difference in cardiovascular disease pattern. *Eur J Endocrinol* 2014; 170: 809–819.

Klawer M, de Blok CIM, Wiepjes CM, et al. Changes in regional body fat, lean body mass and body shape in trans persons using cross-sex hormonal therapy: results from a multicenter prospective study. *Eur J Endocrinol* 2018; 178: 163–171.

Giltay EJ, Elbers JM, Gooren LJ, et al. Visceral fat accumulation is an important determinant of PAI-1 levels in young, nonobese men and women: modulation by
cross-sex hormone administration. *Arterioscler Thromb Vasc Biol* 1998; 18: 1716–1722.

47. Wierckx K, Van Caenegem E, Schreiner T, et al. Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence. *J Sex Med* 2014; 11: 1999–2011.

48. Auer MK, Cecil A, Roepke Y, et al. 12-months metabolic changes among gender dysphoric individuals under cross-sex hormone treatment: a targeted metabolomics study. *Sci Rep* 2016; 6: 37005.

49. Quiros C, Patrasciou I, Mora M, et al. Effect of cross-sex hormone treatment on cardiovascular risk factors in transsexual individuals. Experience in a specialized unit in Catalonia. *Endocrinol Nutr* 2015; 62: 210–216.

50. Perry IJ, Refsum H, Morris RW, et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. *Lancet* 1995; 346: 1395–1398.

51. Nygård O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. *N Engl J Med* 1997; 337: 230–236.

52. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. *JAMA* 1997; 277: 1775–1781.

53. Jacobsen DW, Gatavis JJ, Green R, et al. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects. *Clin Chem* 1994; 40: 873–881.

54. Giltay EJ, Hoogeveen EK, Elbers JM, et al. Effects of sex steroids on plasma total homocysteine levels: a study in transsexual males and females. *J Clin Endocrinol Metab* 1998; 83: 550–553.

55. Giltay EJ, Verhoeof P, Gooren LJ, et al. Oral and transdermal estrogens both lower plasma total homocysteine in male-to-female transsexuals. *Atherosclerosis* 2003; 168: 139–146.

56. Giltay EJ, Gooren LJ, Emeis JJ, et al. Oral ethinyl estradiol, but not transdermal 17beta-estradiol, increases plasma C-reactive protein levels in men. *Thromb Haemost* 2000; 84: 359–360.

57. Giltay EJ, Gooren LJ, Emeis JJ, et al. Oral, but not transdermal, administration of estrogens lowers tissue-type plasminogen activator levels in humans without affecting endothelial synthesis. *Arterioscler Thromb Vasc Biol* 2000; 20: 1396–1403.

58. Gooren LJ and Giltay EJ. Men and women, so different, so similar: observations from cross-sex hormone treatment of transsexual subjects. *Andrologia* 2014; 46: 570–575.

59. Velho I, Fighera TM, Ziegelmann PK, et al. Effects of testosterone therapy on BMI, blood pressure, and laboratory profile of transgender men: a systematic review. *Andrology* 2017; 5: 881–888.

60. Mueller A, Kiesewetter F, Binder H, et al. Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals. *J Clin Endocrinol Metab* 2007; 92: 3470–3475.

61. Mueller A, Haebeler L, Zollver H, et al. Effects of intramuscular testosterone undecanoate on body composition and bone mineral density in female-to-male transsexuals. *J Sex Med* 2010; 7: 3190–3198.

62. Giltay EJ, Toorians AW, Sarabdjitsingh AR, et al. Established risk factors for coronary heart disease are unrelated to androgen-induced baldness in female-to-male transsexuals. *J Endocrinol* 2004; 180: 107–112.

63. van Kesteren PJ, Asscheman H, Megens JA, et al. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. *Clin Endocrinol (Oxf)* 1997; 47: 337–342.

64. Kidd JD, Dolezal C and Bockting WO. The relationship between tobacco use and legal document gender-marker change, hormone use, and gender-affirming surgery in a United States sample of trans-feminine and trans-masculine individuals: implications for cardiovascular health. *LGBT Health* 2018; 5: 401–411.

65. Herbst JH, Jacobs ED, Finlayson TJ, et al. Estimating HIV prevalence and risk behaviors of transgender persons in the United States: a systematic review. *AIDS Behav* 2008; 12: 1–17.

66. Baral SD, Poteat T, Strömdahl S, et al. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. *Lancet Infect Dis* 2013; 13: 214–222.

67. Demir OM, Candilio L, Fuster D, et al. Cardiovascular disease burden among human immunodeficiency virus-infected individuals. *Int J Cardiol* 2018; 265: 195–203.

68. Gogia S, Coromilas A, Regan S, et al. Cardiovascular risk profile of transgender women with HIV: a US Health Care Database Study. *J Acquir Immune Defic Syndr* 2018; 79: e39–e41.

69. Lagraauw HM, Kuiper J and Bot I. Acute and chronic psychological stress as risk factors for cardiovascular disease: insights gained from epidemiological, clinical and experimental studies. *Brain Behav Immun* 2015; 50: 18–30.

70. Bockting WO, Miner MH, Swinburne Romine RE, et al. Stigma, mental health, and resilience in an online sample of the US transgender population. *Am J Public Health* 2013; 103: 943–951.

71. Coleman E, Bockting W, Botzer M, et al. Standards of care for the health of transgender, transgender, and gender-nonconforming people, Version 7. *Int J Transgend* 2011; 13: 165–232.

72. White Hughto JM and Reisner SL. A systematic review of the effects of hormone therapy on psychological functioning and quality of life in transgender individuals. *Transgend Health* 2016; 1: 21–31.

73. Asscheman H, Gooren LJ and Eklund PL. Mortality and morbidity in transsexual patients with cross-gender hormone treatment. *Metab Clin Exp* 1989; 38: 869–873.

74. Nota NM, Wiepjes CM, de Blok CJM, et al. The occurrence of acute cardiovascular events in transgender individuals receiving hormone therapy: results from a large cohort study. *Circulation* 2019; 139:1461–1462.
75. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. *JAMA* 2013; 310: 1353–1368.

76. Ensrud KE, Guthrie KA, Hohensee C, et al. Effects of estradiol and venlafaxine on insomnia symptoms and sleep quality in women with hot flashes. *Sleep* 2015; 38: 97–108.

77. Boardman HM, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in postmenopausal women. *Cochrane Database Syst Rev* 2015; 10: CD002229.

78. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. *Circulation* 2007; 115: 840–845.

79. Lidegaard Ø, Lokkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. *N Engl J Med* 2012; 366: 2257–2266.

80. Burkman RT. Oral contraceptives: an update. *Drugs Today (Today)* 1999; 35: 857–866.

81. Zeitoun K and Carr BR. Is there an increased risk of stroke associated with oral contraceptives? *Drug Saf* 1999; 20: 467–473.

82. Mishell DR. Oral contraception: past, present, and future perspectives. *Int J Fertil* 1991; 36: 7–18.

83. Freedman J, Glueck CJ, Prince M, et al. Testosterone, thrombophilia, thrombosis. *Transl Res* 2015; 165: 537–548.

84. Houghton DE, Alsawas M, Barrionuevo P, et al. Testosterone therapy and venous thromboembolism: a systematic review and meta-analysis. *Thromb Res* 2018; 172: 94–103.

85. Toorians AW, Thomassen MC, Zweegman S, et al. Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. *J Clin Endocrinol Metab* 2003; 88: 5723–5729.

86. Seal LJ, Franklin S, Richards C, et al. Predictive markers for mammoplasty and a comparison of side effect profiles in transwomen taking various hormonal regimens. *J Clin Endocrinol Metab* 2012; 97: 4422–4428.

87. Sitruk-Ware R, Nath A and Mishell DR. Contraception technology: past, present and future. *Contraception* 2013; 87: 319–330.

88. Pomp ER, Rosendaal FR and Doggen CJ. Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. *Am J Hematol* 2008; 83: 97–102.

89. Ahmad S, Barrett J, Beaini AY, et al. Gender dysphoria services: a guide for general practitioners and other healthcare staff. *J Sex Rel Therapy* 2013; 28: 172–185.

90. Seal LJ. A review of the physical and metabolic effects of cross-sex hormonal therapy in the treatment of gender dysphoria. *Ann Clin Biochem* 2016; 53: 10–20.

91. Gava G, Cerpolini S, Martelli V, et al. Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness. *Clin Endocrinol (Endocrinol)* 2016; 85: 239–246.